Cover Image
市場調查報告書

轉移性前列腺癌症:開發平台分析

Metastatic Prostate Cancer - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 251588
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
轉移性前列腺癌症:開發平台分析 Metastatic Prostate Cancer - Pipeline Review, H2 2015
出版日期: 2015年07月31日 內容資訊: 英文 95 Pages
簡介

所謂轉移性前列腺癌症,是從前列腺轉移到人體其他部位的晚期癌症。要的症狀為骨頭痛&腰痛&骨盆痛、體重降低、嗜眠、淋巴節肥大化、皮膚&腸的出血等。主要的治療方法有外科手術和荷爾蒙療法、化療、放射線治療等。

本報告提供全球各國的轉移性前列腺癌症治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

轉移性前列腺癌症概要

治療藥的開發

  • 轉移性前列腺癌症的開發中產品:概要
  • 轉移性前列腺癌症的開發中產品:比較分析

各企業開發中的轉移性前列腺癌症治療藥

大學/研究機關研究中的轉移性前列腺癌症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

轉移性前列腺癌症治療藥:開發中的產品一覽(各企業)

轉移性前列腺癌症治療藥:研究中的產品一覽(各大學/研究機關)

開發轉移性前列腺癌症治療藥的企業

  • Actinium Pharmaceuticals, Inc.
  • Camurus AB
  • Dongkook Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • EntreChem, S.L.
  • Johnson & Johnson
  • MedImmune, LLC
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • OncoMax
  • OXiGENE, Inc.
  • Progenics Pharmaceuticals, Inc.
  • ValiRx Plc

轉移性前列腺癌症:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • abiraterone acetate
  • Actimab-P
  • AST-VAC-1
  • CADD-522
  • Cell Therapy to Target PSMA for Metastatic Prostate Cancer
  • EC-7073
  • HepIn-13
  • KGP-94
  • landogrozumab
  • leuprolide acetate
  • MEDI-6469
  • MIP-1095
  • MVI-118
  • OMRCA-01
  • pracinostat
  • Recombinant Protein for Oncology
  • triptorelin pamoate
  • Vaccine For Oncolytic Newcastle Disease Virus
  • VAL-201
  • vorinostat

轉移性前列腺癌症治療藥:開發中產品的最新趨勢

轉移性前列腺癌症治療藥:開發暫停的產品

轉移性前列腺癌症治療藥:開發中止的產品

轉移性前列腺癌症相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6865IDB

Summary

Global Markets Direct's, 'Metastatic Prostate Cancer - Pipeline Review, H2 2015', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Prostate Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Prostate Cancer - Overview
    • Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis
  • Metastatic Prostate Cancer - Therapeutics under Development by Companies
  • Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Prostate Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Prostate Cancer - Products under Development by Companies
  • Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Prostate Cancer - Companies Involved in Therapeutics Development
    • Actinium Pharmaceuticals, Inc.
    • Camurus AB
    • Dongkook Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • EntreChem, S.L.
    • Johnson & Johnson
    • MedImmune, LLC
    • MEI Pharma, Inc.
    • Merck & Co., Inc.
    • OncoMax
    • OXiGENE, Inc.
    • Progenics Pharmaceuticals, Inc.
    • ValiRx Plc
  • Metastatic Prostate Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abiraterone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-P - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AST-VAC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CADD-522 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target PSMA for Metastatic Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EC-7073 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HepIn-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KGP-94 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • landogrozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEDI-6469 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIP-1095 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVI-118 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMRCA-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triptorelin pamoate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Prostate Cancer - Recent Pipeline Updates
  • Metastatic Prostate Cancer - Dormant Projects
  • Metastatic Prostate Cancer - Discontinued Products
  • Metastatic Prostate Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2015: Cleveland Clinic Researcher Discovers Metabolite of Prostate Cancer Drug more Effective at Treating Aggressive Tumors
      • Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
      • Feb 06, 2014: ZYTIGA Now Reimbursed in Quebec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer
      • Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy
      • May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer
      • Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients
      • May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer
      • Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Prostate Cancer, H2 2015
  • Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Camurus AB, H2 2015
  • Metastatic Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Metastatic Prostate Cancer - Pipeline by EntreChem, S.L., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Johnson & Johnson, H2 2015
  • Metastatic Prostate Cancer - Pipeline by MedImmune, LLC, H2 2015
  • Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Merck & Co., Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by OncoMax, H2 2015
  • Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by ValiRx Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Metastatic Prostate Cancer - Dormant Projects, H2 2015
  • Metastatic Prostate Cancer - Dormant Projects (Contd..1), H2 2015
  • Metastatic Prostate Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Metastatic Prostate Cancer, H2 2015
  • Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top